Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;61(7):703-711.
doi: 10.1007/s12275-023-00062-4. Epub 2023 Jun 26.

Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches

Hee-Jung Lee  1 , Hanul Choi  1 , Aleksandra Nowakowska  1 , Lin-Woo Kang  2 , Minjee Kim  3 , Young Bong Kim  4
Affiliations

Antiviral Activity Against SARS-CoV-2 Variants Using in Silico and in Vitro Approaches

Hee-Jung Lee et al. J Microbiol. 2023 Jul.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emergence in 2019 led to global health crises and the persistent risk of viral mutations. To combat SARS-CoV-2 variants, researchers have explored new approaches to identifying potential targets for coronaviruses. This study aimed to identify SARS-CoV-2 inhibitors using drug repurposing. In silico studies and network pharmacology were conducted to validate targets and coronavirus-associated diseases to select potential candidates, and in vitro assays were performed to evaluate the antiviral effects of the candidate drugs to elucidate the mechanisms of the viruses at the molecular level and determine the effective antiviral drugs for them. Plaque and cytopathic effect reduction were evaluated, and real-time quantitative reverse transcription was used to evaluate the antiviral activity of the candidate drugs against SARS-CoV-2 variants in vitro. Finally, a comparison was made between the molecular docking binding affinities of fenofibrate and remdesivir (positive control) to conventional and identified targets validated from protein-protein interaction (PPI). Seven candidate drugs were obtained based on the biological targets of the coronavirus, and potential targets were identified by constructing complex disease targets and PPI networks. Among the candidates, fenofibrate exhibited the strongest inhibition effect 1 h after Vero E6 cell infection with SARS-CoV-2 variants. This study identified potential targets for coronavirus disease (COVID-19) and SARS-CoV-2 and suggested fenofibrate as a potential therapy for COVID-19.

Keywords: Drug repurposing; Fenofibrate; In silico; In vitro assay; SARS-CoV-2.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Batchuluun, B., Pinkosky, S. L., & Steinberg, G. R. (2022). Lipogenesis inhibitors: Therapeutic opportunities and challenges. Nature Reviews Drug Discovery, 21, 283–305. - DOI - PubMed - PMC
    1. Buschard, K. (2020). Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. Medical Hypotheses, 143, 110127. - DOI - PubMed - PMC
    1. Chakraborty, C., Sharma, A. R., Bhattacharya, M., Agoramoorthy, G., & Lee, S. S. (2021). The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: Lessons learned from major clinical studies. Frontiers in Pharmacology, 12, 704205. - DOI - PubMed - PMC
    1. Chakraborty, R., Bhattacharje, G., Baral, J., Manna, B., Mullick, J., Mathapati, B. S., Abraham, P. J. M., Hasija, Y., & Ghosh, A. (2022). In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2. Computers in Biology and Medicine, 147, 105788. - DOI - PubMed - PMC
    1. Chan, J. F., Lau, S. K., To, K. K., Cheng, V. C., Woo, P. C., & Yuen, K. Y. (2015). Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clinical Microbiology Reviews, 28, 465–522. - DOI - PubMed - PMC

Supplementary concepts

LinkOut - more resources